{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:04:53Z","timestamp":1780092293215,"version":"3.54.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T-cell lymphomas (PTCLs) are a biologically diverse and uncommon group of diseases. Compared to their B-cell counterparts, PTCLs remain largely unexplored and the optimal treatment ill-defined due to disease rarity and biological heterogeneity. For the majority of PTCL subtypes, prognosis is poor with a 5-year overall survival of approximately 30% in most series.<\/jats:p><jats:p>The notable exception is ALK-positive anaplastic large-cell lymphoma (ALK-pos ALCL), which has a superior outcome. The international prognostic index can be used to some extent to define risk groups within some PTCL subtypes, including PTCL unspecified (PTCLUS). It is likely that the observed clinical heterogeneity reflects differences at the molecular level. With the more widespread availability of gene expression profiling, it may be possible in the future to further refine the classification of PTCLs and elucidate novel therapeutic targets. Future clinical trials are needed that focus specifically on PTCL to advance our understanding and define the optimal management in this disease.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.267","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T01:29:34Z","timestamp":1132709374000},"page":"267-277","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)"],"prefix":"10.1182","volume":"2005","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702231723900_R1","unstructured":"Banks PM, Warnke RA. Mature T-cell and NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues. IARC Press: Lyon; 2001:189\u2013230."},{"key":"2019111702231723900_R2","doi-asserted-by":"crossref","unstructured":"Kwak LW, Wilson M, Weiss LM, et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol. 1991;9(8):1426\u20131431.","DOI":"10.1200\/JCO.1991.9.8.1426"},{"key":"2019111702231723900_R3","doi-asserted-by":"crossref","unstructured":"Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin\u2019s lymphoma. Blood. 1997;89(12):4514\u20134520.","DOI":"10.1182\/blood.V89.12.4514"},{"key":"2019111702231723900_R4","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood. 1998;92(1):76\u201382."},{"key":"2019111702231723900_R5","doi-asserted-by":"crossref","unstructured":"Morabito F, Gallamini A, Stelitano C, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer. 2004;101(7):1601\u20131608.","DOI":"10.1002\/cncr.20531"},{"key":"2019111702231723900_R6","doi-asserted-by":"crossref","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467\u20131475.","DOI":"10.1093\/annonc\/mdh392"},{"key":"2019111702231723900_R7","unstructured":"Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9(8):849\u2013855."},{"key":"2019111702231723900_R8","doi-asserted-by":"crossref","unstructured":"Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20132479.","DOI":"10.1182\/blood-2003-09-3080"},{"key":"2019111702231723900_R9","doi-asserted-by":"crossref","unstructured":"Mason DY, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas (\u2018Ki-1 lymphoma\u2019) are associated with a chromosomal translocation involving 5q35 [see comments]. Br J Haematol. 1990;74(2):161\u2013168.","DOI":"10.1111\/j.1365-2141.1990.tb02560.x"},{"key":"2019111702231723900_R10","doi-asserted-by":"crossref","unstructured":"Nascimento AF, Pinkus JL, Pinkus GS. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol. 2004;121(5):709\u2013717.","DOI":"10.1309\/GQ2RLNDWLB9WY6UU"},{"key":"2019111702231723900_R11","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997;89(11):3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2019111702231723900_R12","doi-asserted-by":"crossref","unstructured":"Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913\u20133921.","DOI":"10.1182\/blood.V93.11.3913"},{"key":"2019111702231723900_R13","doi-asserted-by":"crossref","unstructured":"ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJ. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43(5):462\u2013469.","DOI":"10.1046\/j.1365-2559.2003.01726.x"},{"key":"2019111702231723900_R14","doi-asserted-by":"crossref","unstructured":"Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin\u2019s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16(1):70\u201377.","DOI":"10.1200\/JCO.1998.16.1.70"},{"key":"2019111702231723900_R15","doi-asserted-by":"crossref","unstructured":"Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216\u2013221.","DOI":"10.1182\/blood-2003-05-1401"},{"key":"2019111702231723900_R16","doi-asserted-by":"crossref","unstructured":"Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99(2):627\u2013633.","DOI":"10.1182\/blood.V99.2.627"},{"key":"2019111702231723900_R17","unstructured":"Jaffe ES, Railfkiaer E. Mature T-cell and NK neoplasms: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues. IARC Press: Lyon; 2001:191\u2013194."},{"key":"2019111702231723900_R18","doi-asserted-by":"crossref","unstructured":"Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102(13):4261\u20134269.","DOI":"10.1182\/blood-2003-05-1675"},{"key":"2019111702231723900_R19","doi-asserted-by":"crossref","unstructured":"Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101(9):3407\u20133412.","DOI":"10.1182\/blood-2002-05-1597"},{"key":"2019111702231723900_R20","doi-asserted-by":"crossref","unstructured":"Wang H, Medeiros LJ, Jones D. Subcutaneous panniculitis-like T-cell lymphoma. Clin Lymph. 2002;3(3):181\u2013183.","DOI":"10.1016\/S1526-9655(11)70265-2"},{"key":"2019111702231723900_R21","doi-asserted-by":"crossref","unstructured":"Shipp M, Harrington D, Chairpersons, et al. A predictive model for aggressive non-Hodgkin\u2019s lymphoma: The International NHL Prognostic Factors Project. N Engl J Med. 1993;329:987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"2019111702231723900_R22","doi-asserted-by":"crossref","unstructured":"Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494\u20135500.","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"2019111702231723900_R23","doi-asserted-by":"crossref","unstructured":"Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood. 2004;103(1):236\u2013241.","DOI":"10.1182\/blood-2002-05-1352"},{"key":"2019111702231723900_R24","doi-asserted-by":"crossref","unstructured":"Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64(6):2127\u20132133.","DOI":"10.1158\/0008-5472.CAN-03-2068"},{"key":"2019111702231723900_R25","unstructured":"Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype [In Process Citation]. Blood. 2000;96(9):2993\u20133000."},{"key":"2019111702231723900_R26","doi-asserted-by":"crossref","unstructured":"Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22(9):1682\u20131688.","DOI":"10.1200\/JCO.2004.10.172"},{"key":"2019111702231723900_R27","doi-asserted-by":"crossref","unstructured":"ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects\u2014a review. J Pathol. 2003;200(1):4\u201315.","DOI":"10.1002\/path.1331"},{"key":"2019111702231723900_R28","doi-asserted-by":"crossref","unstructured":"ten Berge RL, Meijer CJ, Dukers DF, et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood. 2002;99(12):4540\u20134546.","DOI":"10.1182\/blood.V99.12.4540"},{"key":"2019111702231723900_R29","doi-asserted-by":"crossref","unstructured":"Martinez-Delgado B, Melendez B, Cuadros M, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res. 2004;10(15):4971\u20134982.","DOI":"10.1158\/1078-0432.CCR-04-0269"},{"key":"2019111702231723900_R30","unstructured":"Ballester B, Gisselbrecht C, Gaulard P, Houlgatte R, Xerri L. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas [abstract]. Ann Oncol. 2005;16(Supp 5):124a."},{"key":"2019111702231723900_R31","unstructured":"Piccaluga PP, Agostinelli C, Zupo S, et al. Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals the existance of two subgroups related to two cellular counterparts [abstract]. Ann Oncol2005;16(Supp 5):125a."},{"key":"2019111702231723900_R32","doi-asserted-by":"crossref","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20131006.","DOI":"10.1056\/NEJM199304083281404"},{"key":"2019111702231723900_R33","doi-asserted-by":"crossref","unstructured":"Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer. 2005;103(10):2091\u20132098.","DOI":"10.1002\/cncr.20999"},{"key":"2019111702231723900_R34","doi-asserted-by":"crossref","unstructured":"Karakas T, Bergmann L, Stutte HJ, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymph. 1996;24(1\u20132):121\u2013129.","DOI":"10.3109\/10428199609045720"},{"key":"2019111702231723900_R35","doi-asserted-by":"crossref","unstructured":"Wohrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol. 2004;15(11):1680\u20131683.","DOI":"10.1093\/annonc\/mdh427"},{"key":"2019111702231723900_R36","doi-asserted-by":"crossref","unstructured":"Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK\/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54(1):182\u2013190.","DOI":"10.1016\/S0360-3016(02)02916-4"},{"key":"2019111702231723900_R37","doi-asserted-by":"crossref","unstructured":"You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15(4):618\u2013625.","DOI":"10.1093\/annonc\/mdh143"},{"key":"2019111702231723900_R38","doi-asserted-by":"crossref","unstructured":"Rodriguez J, Caballero MD, Gutierrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14(12):1768\u20131775.","DOI":"10.1093\/annonc\/mdg459"},{"key":"2019111702231723900_R39","doi-asserted-by":"crossref","unstructured":"Blystad AK, Enblad G, Kvaloy S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27(7):711\u2013716.","DOI":"10.1038\/sj.bmt.1702867"},{"key":"2019111702231723900_R40","doi-asserted-by":"crossref","unstructured":"Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;23(5):437\u2013442.","DOI":"10.1038\/sj.bmt.1701596"},{"key":"2019111702231723900_R41","unstructured":"Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem cell transplantation in induction failure patients with peripheral T-cell lymphoma: the GEL\/TAMO experience [abstract]. Blood. 2003;102(11):2710a."},{"key":"2019111702231723900_R42","doi-asserted-by":"crossref","unstructured":"Reimer P, Schertlin T, Rudiger T, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J. 2004;5(4):304\u2013311.","DOI":"10.1038\/sj.thj.6200359"},{"key":"2019111702231723900_R43","doi-asserted-by":"crossref","unstructured":"Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, Shyr Y, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymph. 2004;45(11):2261\u20132267.","DOI":"10.1080\/10428190412331272749"},{"key":"2019111702231723900_R44","doi-asserted-by":"crossref","unstructured":"Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120(6):978\u2013985.","DOI":"10.1046\/j.1365-2141.2003.04203.x"},{"key":"2019111702231723900_R45","doi-asserted-by":"crossref","unstructured":"Zamkoff KW, Matulis MD, Mehta AC, Beaty MW, Hutchison RE, Gentile TC. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant. 2004;33(6):635\u2013638.","DOI":"10.1038\/sj.bmt.1704392"},{"key":"2019111702231723900_R46","doi-asserted-by":"crossref","unstructured":"Kahl C, Leithauser M, Wolff D, et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol. 2002;81(11):646\u2013650.","DOI":"10.1007\/s00277-002-0556-2"},{"key":"2019111702231723900_R47","doi-asserted-by":"crossref","unstructured":"Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22(11):2172\u20132176.","DOI":"10.1200\/JCO.2004.12.050"},{"key":"2019111702231723900_R48","doi-asserted-by":"crossref","unstructured":"Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol2001;113(1):185\u2013187.","DOI":"10.1046\/j.1365-2141.2001.02743.x"},{"key":"2019111702231723900_R49","doi-asserted-by":"crossref","unstructured":"Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Canellos G, Cheson BD. CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL [abstract]. Blood2004;104(11):2486a.","DOI":"10.1182\/blood.V104.11.2486.2486"},{"key":"2019111702231723900_R50","doi-asserted-by":"crossref","unstructured":"Dang NH, Pro B, Hagemeister FB, et al. Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed\/refractory T-cell non-Hodkin\u2019s lympoma [abstract]. Blood. 2004;104(11):2641a.","DOI":"10.1182\/blood.V104.11.2641.2641"},{"key":"2019111702231723900_R51","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995;86(11):4063\u20134075.","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"},{"key":"2019111702231723900_R52","doi-asserted-by":"crossref","unstructured":"Piekarz RL, Frye R, Turner M, et al. Responses and molecular markers in patients with peripheral t-cell lymphoma treated on a phase II trial of depsipeptide, FK228. Proc ASCO. 2005;24:3061a.","DOI":"10.1200\/jco.2005.23.16_suppl.3061"},{"key":"2019111702231723900_R53","doi-asserted-by":"crossref","unstructured":"Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920\u20132924.","DOI":"10.1182\/blood-2003-10-3389"},{"key":"2019111702231723900_R54","doi-asserted-by":"crossref","unstructured":"Weidmann E, Hess G, Krause SW, et al. Combination chemo-immunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin is an effective first-line regimen in peripheral T-cell lymphoma [abstract]. Blood. 2004;104(11):2640a.","DOI":"10.1182\/blood.V104.11.2640.2640"},{"key":"2019111702231723900_R55","doi-asserted-by":"crossref","unstructured":"Forero-Torres A, Bernstein S, Gopal A, et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma [abstract]. Blood. 2004;104(11):2637a.","DOI":"10.1200\/jco.2005.23.16_suppl.6601"},{"key":"2019111702231723900_R56","doi-asserted-by":"crossref","unstructured":"Ansell SM, Byrd JC, Horwitz SM, et al. Phase I\/II open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory\/relapsed CD30 positive lypmphoma [abstract]. Blood. 2004;104(104):2636a.","DOI":"10.1182\/blood.V104.11.2636.2636"},{"key":"2019111702231723900_R57","doi-asserted-by":"crossref","unstructured":"Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2004;10(22):7529\u20137539.","DOI":"10.1158\/1078-0432.CCR-04-0983"},{"key":"2019111702231723900_R58","doi-asserted-by":"crossref","unstructured":"Passoni L, Gambacorti-Passerini C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymph. 2003;44(10):1675\u20131681.","DOI":"10.1080\/1042819031000099625"},{"key":"2019111702231723900_R59","doi-asserted-by":"crossref","unstructured":"Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol. 2004;15(10):1447\u20131449.","DOI":"10.1093\/annonc\/mdh409"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/267\/645306\/267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/267\/645306\/267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T06:40:34Z","timestamp":1626763234000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/267\/19329\/Aggressive-Peripheral-TCell-Lymphomas-Specified"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.267","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}